ACCEPTED FOR USE
- Xolair (omalizumab) as add-on therapy in severe persistent allergic asthma.
- Januvia (sitagliptin) for treatment of type II diabetes mellitus in combination with metformin.
- Budenofalk (budesonide) for ulcerative colitis of the rectum and sigmoid colon.
- Invanz (ertapenum) for prophylaxis of surgical site infection following elective colorectal surgery.
- Atimos Modulite (formoterol) for coronary obstructive pulmonary disease.
REJECTED FOR USE
- Cipralex (escitalopram) for obsessive compulsive disorder.
- Prialt (ziconotide) for treatment of severe, chronic pain.
- Cystadane (betaine) as adjunctive treatment of homocystinuria.
Further information: The Scottish Medicines Consortium
